Why Is Renin Monitoring Important in Primary Aldosteronism?
At a Glance
Renin monitoring helps assess whether spironolactone is adequately blocking the effects of excess aldosterone in primary aldosteronism. A rising renin can support treatment effectiveness, but results must be interpreted alongside blood pressure, potassium, kidney function, other medicines, and the specific renin test used.
In this answer
4 sections
When you take spironolactone (a type of medication called a mineralocorticoid receptor antagonist or MRA) for primary aldosteronism, your doctor will regularly check your blood pressure and potassium levels. They may also order blood tests to monitor your renin levels, along with your kidney function (creatinine or eGFR).
Renin is an enzyme produced by your kidneys that helps regulate blood pressure. In primary aldosteronism, excess aldosterone causes your body to hold onto salt and water. This extra volume signals your kidneys to stop producing renin, resulting in a state called suppressed renin [1].
Monitoring renin can be a helpful clue for your care team because your blood pressure and potassium can sometimes return to normal before the medication has fully reduced the excess aldosterone’s internal effects on your body [2].
Why Normal Blood Pressure May Not Be the Only Goal
It can be unsettling to hear that your doctor wants to monitor more labs or adjust your medication when your blood pressure readings are perfect and you feel well. The reason is that long-term, excess aldosterone can increase the risk of cardiovascular (heart and blood vessel) issues.
Observational studies suggest that patients whose renin remains suppressed during treatment have a higher risk of cardiovascular events, such as heart attacks, compared to those whose renin levels rise [3][4]. Some research also suggests a link between persistent renin suppression and a faster decline in kidney function over time [5].
However, it is important to know that a suppressed renin result is just a biomarker (a biological clue)—it does not prove you already have organ damage, nor does it guarantee that increasing your medication will perfectly prevent future issues [3].
Understanding Treatment Goals (The PAMO Framework)
To help standardize how doctors evaluate primary aldosteronism treatment, experts developed a consensus framework called the Primary Aldosteronism Medical Treatment Outcome (PAMO) criteria [6]. PAMO outlines both clinical and biochemical goals to strive for, though they are general targets, not a strict pass/fail test:
- Clinical goals: Normalizing blood pressure using the fewest possible medications [7]. (Needing multiple medications does not mean you have “failed” treatment—it is very common.)
- Biochemical (internal) goals: Normalizing potassium without needing potassium supplements, and seeing an increase in renin levels [1].
Interpreting Your Renin Results
Spironolactone competes with aldosterone to bind to receptors in your body. As the medication blocks aldosterone from causing salt and water retention, your body sheds excess volume. In response, your kidneys usually realize they no longer need to suppress renin, and your renin levels rise [8][9].
- Suppressed Renin: A persistently low renin level might suggest the current medication dose isn’t fully blocking the aldosterone [2]. However, renin is not a perfect standalone measure. Many other things can keep renin low, including high salt intake, older age, kidney disease, and other medications like beta-blockers [10][9].
- Unsuppressed Renin: If your renin rises above a certain threshold, it suggests the medication is effectively blocking the hormone [11]. The target depends on the specific lab test used. For a Plasma Renin Activity (PRA) test, a common goal in studies is 1.0 ng/mL/h or higher [3][12]. If your lab uses a Direct Renin Concentration (DRC) test, the numbers and units will be completely different.
Adjusting Your Medication Safely
The 2025 Endocrine Society guidelines suggest that if your blood pressure is difficult to control or your renin remains suppressed, your doctor might consider adjusting (titrating) your MRA dose [2].
However, increasing spironolactone is not an automatic decision. Higher doses can cause low blood pressure, dehydration, worsening kidney function, and dangerously high potassium (hyperkalemia). The risks are even higher if you have underlying kidney issues or take other medications like ACE inhibitors, ARBs, NSAIDs, or antibiotics like trimethoprim [2]. Your clinician must balance the potential benefits of raising your renin against these safety limits.
Important Patient Safety Tips:
- Do not change your routine: Never adjust your spironolactone, stop your other medications, or change your diet/salt intake just to manipulate a renin test. Always follow your ordering clinician’s preparation plan.
- Monitor kidney function: Every time your dose is increased, your doctor should recheck your potassium and your kidney function (creatinine/eGFR) shortly afterward to ensure the new dose is safe [13].
- Avoid hidden potassium: Do not use potassium supplements or potassium-enriched salt substitutes without your doctor’s explicit approval.
Common questions in this guide
Why is renin checked when I take spironolactone for primary aldosteronism?
What does it mean if my renin is still suppressed during treatment?
What renin level should I aim for?
Why are potassium and kidney tests checked with renin?
Should I increase spironolactone if my renin remains low?
Can my blood pressure and potassium be normal even if my renin is suppressed?
Related questions
Show more
Get notified when new evidence is published on hyperaldosteronism.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Hundemer GL, Leung AA, Kline GA, et al.
Endocrine reviews 2024; (45(1)):69-94 doi:10.1210/endrev/bnad024.
PMID: 37439256 - 2
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.
Adler GK, Stowasser M, Correa RR, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.
PMID: 40658480 - 3
Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis.
Katsuragawa S, Le MV, Fuller PJ, Yang J
The lancet. Diabetes & endocrinology 2025; (13(12)):1041-1053 doi:10.1016/S2213-8587(25)00263-3.
PMID: 41235994 - 4
Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Hundemer GL, Curhan GC, Yozamp N, et al.
The lancet. Diabetes & endocrinology 2018; (6(1)):51-59 doi:10.1016/S2213-8587(17)30367-4.
PMID: 29129576 - 5
Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S, Goto A, Shinoda S, et al.
Hypertension (Dallas, Tex. : 1979) 2023; (80(9)):1909-1920 doi:10.1161/HYPERTENSIONAHA.123.21096.
PMID: 37449450 - 6
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.
Yang J, Burrello J, Goi J, et al.
The lancet. Diabetes & endocrinology 2025; (13(2)):119-133 doi:10.1016/S2213-8587(24)00308-5.
PMID: 39824204 - 7
Treatment of Primary Aldosteronism.
Parisien-La Salle S, Hundemer GL, Nehs MA, et al.
Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.
PMID: 41808633 - 8
Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
Yoshida Y, Fujiki R, Kinoshita M, et al.
Hypertension research : official journal of the Japanese Society of Hypertension 2023; (46(1)):100-107 doi:10.1038/s41440-022-01045-5.
PMID: 36229529 - 9
Antihypertensive effects and changes in extracellular water content by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Matsuda N, Yoshida Y, Inobe N, et al.
Hypertension research : official journal of the Japanese Society of Hypertension 2025; (48(2)):553-562 doi:10.1038/s41440-024-01997-w.
PMID: 39543416 - 10
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y, Turcu AF
Frontiers in endocrinology 2021; (12()):625457 doi:10.3389/fendo.2021.625457.
PMID: 33841329 - 11
Aldosterone-mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism.
Yoshida Y, Shibata H
Hypertension research : official journal of the Japanese Society of Hypertension 2026; (49(4)):1336-1342 doi:10.1038/s41440-026-02561-4.
PMID: 41629686 - 12
Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial.
Merabtine A, Leung AA, Kline GA, et al.
BMJ open 2025; (15(12)):e111167 doi:10.1136/bmjopen-2025-111167.
PMID: 41419284 - 13
Outcomes of drug-based and surgical treatments for primary aldosteronism.
Steichen O, Lorthioir A, Zinzindohoue F, et al.
Advances in chronic kidney disease 2015; (22(3)):196-203.
PMID: 25908468
This page is for informational purposes only and does not constitute medical advice. It explains general monitoring during treatment for primary aldosteronism; your clinician should interpret your results and adjust medication for your individual situation.